|
Pat
|
W
|
Sex
|
Age (years)
|
Disease duration (years)
|
CRP
|
Medication
|
DAS28
|
Clinical response
|
HMGB1 protein
|
HMGB1mRNA
|
|---|
| | | | | | |
MTX
|
Pred
| |
DAS28
|
ACR
|
ES
|
CG
| |
|---|
|
1
|
0
|
F
|
55
|
18
|
107
|
17.5
|
5 *
|
6.71
| | |
1.5
|
1
| |
| |
9
| | | |
38
| | |
6.34
|
No
|
0
|
2
|
1.5
| |
|
2
|
0
|
F
|
52
|
6
|
14
|
7.5
|
7.5
|
6.00
| | |
1.5
|
1.5
| |
| |
9
| | | |
15
| | |
4.43
|
Mod
|
20
|
1
|
0.5
|
0
|
|
3
|
0
|
F
|
58
|
2
|
46
|
10
| |
7.91
| | |
3
|
4
| |
| |
9
| | | |
25
| | |
5.41
|
Mod
|
50
|
1
|
1.5
|
0
|
|
4
|
0
|
F
|
57
|
4
|
7
|
10
| |
4.94
| | |
2
|
2
| |
| |
9
| | | |
34
| | |
4.41
|
No
|
20
|
2
|
2
|
Up
|
|
5
|
0
|
M
|
56
|
7
|
44
|
15
| |
5.95
| | |
2
|
2.5
| |
| |
9
| | | |
7
| | |
2.90
|
G
|
70
|
3.5
|
3
| |
|
6
|
0
|
F
|
69
|
1
|
69
|
15
|
5
|
7.39
| | |
2
|
3
| |
| |
9
| | | |
7
| | |
1.79
|
G
|
70
|
1.5
|
2.5
|
Up
|
|
7
|
0
|
F
|
66
|
14
|
34
|
10
| |
5.64
| | |
2
|
2
| |
| |
9
| | | |
16
| | |
4.73
|
Mod
|
0
|
1
|
0.5
|
Down
|
|
8
|
0
|
F
|
66
|
10
|
18
|
12.5
| |
4.83
| | |
3.5
|
4
| |
| |
9
| | | |
19
| | |
4.23
|
Mod
|
0
|
0.5
|
2
|
Down
|
|
9
|
0
|
M
|
25
|
0.6
|
26
|
17.5
|
7.5
|
5.62
| | |
.5
|
3
| |
| |
9
| | | |
25
| | |
3.91
|
Mod
|
20
|
3
|
4
| |
- * Patient 1 also received 150 mg/day cyclosporine before and during the study period.Pat = Patient, W = week, CRP = C-reactive protein, MTX = Methotrexate (mg/week), Pred = Prednisone (mg/day), DAS28 = disease activity score calculated on 28 joints, ACR = American College of Rheumatology, HMGB1 = High-mobility group box chromosomal protein 1, ES = Erik Sundberg, CG = Cecilia Grundtman, F = Female, M = Male, No = Non, Mod = Moderate, G = Good.
